Centaurin β5 Inhibitors
Centaurin β5 inhibitors encompass a range of chemical compounds that interfere with various signaling pathways integral to the protein's function. LY 294002 and Wortmannin operate by blocking PI3K activity, thereby curtailing the PI3K/Akt pathway and subsequently diminishing the role of Centaurin β5 within this cascade. Rapamycin takes a different approach, targeting the mTOR complex, which is a downstream component of the PI3K/Akt pathway, leading to a similar outcome of functional inhibition of Centaurin β5. Other inhibitors,like PD 98059 and SB 203580, impede the MAPK pathway at the MEK and p38 MAPK junctures respectively, potentially reducing the activity of Centaurin β5 if it relies on this pathway for activation. PP 2 and SP600125 add to this arsenal by inhibiting Src family kinases and JNK, which, in cases where Centaurin β5's functionality hinges on these kinases, results in diminished activity of the protein.
Further expanding the toolkit, U0126, BKM120, PI-103, GSK 690693, and ZSTK474 all contribute to the suppression of Centaurin β5 by targeting various nodes within the PI3K/Akt/mTOR signaling network; U0126 by inhibiting MEK1/2, BKM120, PI-103, and ZSTK474 by inhibiting PI3K activity, and GSK 690693 by directly targeting Akt. The collective action of these inhibitors leads to a concerted downregulation of Centaurin β5 activity by impeding the protein's activation signals. Each inhibitor operates by interrupting the necessary upstream events that are prerequisites for Centaurin β5's functionality, thereby ensuring that the protein's activity is effectively diminished without affecting its expression levels. This precise targeting makes these chemicals potent tools in the selective inhibition of Centaurin β5's role within cellular signaling processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3Ks), LY 294002 leads to the inhibition of the downstream Akt signaling pathway. Centaurin β5, being a PI3K-Akt pathway component, is functionally diminished by this inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly inhibits the enzyme, leading to the blockade of the PI3K/Akt pathway. This indirectly diminishes the activity of Centaurin β5 by preventing its necessary activation signals. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin disrupts the mTOR pathway which is downstream of PI3K/Akt signaling. By inhibiting mTOR, the activity of Centaurin β5 is indirectly diminished as it is a downstream effector in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
By inhibiting MEK, which is upstream of ERK1/2 in the MAPK pathway, PD 98059 can indirectly diminish the activity of Centaurin β5 if its activity is ERK-dependent, as it prevents the necessary phosphorylation events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAPK, potentially reducing the activity of Centaurin β5 if its activity is contingent upon signals from the p38 MAPK pathway by preventing phosphorylation events within the pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP 2 is a Src family kinase inhibitor. If Centaurin β5 activity is modulated by Src kinase signaling, PP2 would diminish its function by inhibiting the upstream kinases necessary for Centaurin β5 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 would lead to decreased Centaurin β5 activity if JNK signaling is necessary for the full functional expression of Centaurin β5. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK1/2 inhibitor that prevents the activation of ERK1/2. If Centaurin β5 relies on ERK-mediated signaling for its activity, U0126 would indirectly diminish its function by inhibiting upstream kinases. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
BKM120, a PI3K inhibitor, would decrease the activity of Centaurin β5 by blocking the PI3K/Akt signaling pathway, assuming Centaurin β5 is functionally linked to this pathway. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $33.00 $131.00 | 3 | |
PI-103 is a dual PI3K/mTOR inhibitor, thereby dampening the PI3K/Akt/mTOR signaling pathway. This would lead to reduced activity of Centaurin β5 if it is a downstream component of this pathway. | ||||||